ADVANCED SOLID TUMOR

This early-phase study tested a new drug called BRY805 in 13 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose for future studies. The trial was terminated early, so results ar…

This early-phase study tested a new drug (M9466) combined with chemotherapy in people with advanced solid tumors, including colorectal cancer. The main goal was to check safety and find the right dose. Only 3 people took part before the study was stopped early.

This study tested a drug called serabelisib combined with a diet that lowers insulin levels, with or without another chemotherapy drug, in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The goal was to see if the diet could reduce side ef…

This early-stage study tested a new drug called NB004 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and how the drug moves through the body. The trial was terminated early, so results are limited.

This study tested a treatment called TIL therapy for people with advanced solid tumors. Doctors take immune cells from a patient's tumor, grow them in a lab, and put them back into the patient to attack the cancer. The goal was to check safety and see if tumors shrink. The study …

This early-stage study tested a new drug called RiMO-401 given as an injection directly into tumors, combined with radiation, for people with advanced solid cancers that could not be cured. Only 5 participants were enrolled before the study was stopped. The main goal was to find …

This early-stage study tested an experimental pill called PRT7732 in people with advanced solid tumors that have a specific genetic mutation (SMARCA4). The main goals were to check safety, find the right dose, and see if the drug shrinks tumors. The study was terminated early, an…

This study tested a new drug called NUV-868, alone or with other cancer drugs (olaparib or enzalutamide), in 82 adults with advanced solid tumors like ovarian, pancreatic, prostate, or breast cancer. The main goals were to check safety and find the right dose. The trial was stopp…

This study tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors (colorectal, nasopharyngeal, or lung cancer). The goal was to find a safe dose and see if the combo could control the disease. The trial was terminated early, so result…

This early-stage study tested an experimental oral drug called NKT3447 in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This early-phase trial tested a new drug, DCC-3084, alone or with other treatments, in people with advanced solid tumors linked to MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and check if tumors shrank. It was termin…

This study tested a combination of two experimental drugs, mirdametinib and BGB-3245, in adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the combo could shrink tumors. The study was terminated early…

This study tested an experimental drug called ART0380 in 36 people with advanced or metastatic solid tumors, including endometrial cancer. The goal was to see if the drug could shrink tumors. The trial was terminated early, so results are limited. Participants had to have finishe…

This early-phase study tested a new drug called PHN-010, which delivers a powerful toxin directly to cancer cells. It involved 26 adults with advanced lung, colon, endometrial, ovarian, or cervical cancers that had already been treated. The main goals were to check safety and fin…

This early-stage trial tested an experimental pill called RP-1664 in people with advanced solid tumors that had stopped responding to other treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was stopped early, so results are limited.

This early-stage trial tested a new drug called RP-3467, alone or with another drug (olaparib), in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated early, s…

This study tested an experimental drug called TransCon TLR7/8 Agonist, alone or with another drug (pembrolizumab), in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. The trial was t…

This study tested a new drug, GEN1286, in 23 adults with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and whether it could shrink tumors. The trial was terminated early, so results are limited.

This study tested a new drug (PRT3789) combined with the immunotherapy pembrolizumab in people with advanced cancers that have a specific genetic change called SMARCA4. The goal was to see if the combination was safe and could shrink tumors. The study was terminated early after e…

This early-stage trial tested a new drug, DCC-3116, alone or with other targeted therapies, in 91 adults with advanced solid tumors (like lung cancer) that have specific gene mutations. The study was terminated, meaning it stopped early, likely due to safety or lack of benefit. T…

This study tested a new drug called LB101 in 25 adults with advanced solid tumors that had not responded to standard treatments. The goal was to check safety and see if the drug could shrink tumors. However, the trial was stopped early, so we have limited information on how well …

This early-stage study tested an experimental virus therapy called VAXINIA (CF33-hNIS) in 66 adults with advanced solid tumors that had spread. The virus was given either directly into tumors or through a vein, alone or with the immunotherapy drug pembrolizumab. The main goal was…

This early-phase study tested a new experimental drug, BGB-A3055, alone or with another drug (tislelizumab), in people with advanced solid tumors that had spread. The main goals were to check safety, how the body handles the drug, and whether it shrinks tumors. The study was term…

This early-stage trial aimed to test the safety and best dose of combining two drugs (adagrasib and olaparib) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study focused on certain cancers like gynecological, breast, pancreatic, a…

This study tested a combination of two drugs, SON-1010 and atezolizumab, in people with advanced solid tumors and platinum-resistant ovarian cancer. The goal was to see if the combo was safe and could slow cancer growth. The study was terminated early, so results are limited. It …

This study tested a new drug called JSKN033 in 11 people with advanced solid tumors that have a protein called HER2. The goal was to see if the drug is safe and what dose works best. The trial was stopped early, so results are limited.

This early-stage study tested a new drug (RP-6306) combined with standard chemotherapy (FOLFIRI) in 38 adults with advanced solid tumors, including colorectal, GI, and esophageal cancers that had stopped responding to other treatments. The main goals were to check safety, find th…

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors (like lung or colon cancer) that have specific KRAS gene mutations. The main goals were to check safety and find the right dose. The study was…

This early-stage study tested a new drug, BGB-B3227, alone or with another drug (tislelizumab) in 35 people with advanced solid tumors. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This early-stage study aimed to see how a new drug called S095012 spreads through the body and reaches tumors in people with advanced solid cancers. Only 3 participants were enrolled before the study was stopped early. The main goal was to use PET scans to track the drug, not to …